StockData
20/20 Biolabs, Inc. logo

20/20 Biolabs, Inc. (AIDX) stock

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19+0.00 (+1.30%)

Close on Nov 17, 2026Market cap $2.39MP/E –Yield –

20/20 Biolabs r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $592.57K, down 53.0% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$592.57K-53.0%
FY2024Dec 31, 2024$1.26M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$257.63K–
Q1 FY2026Mar 31, 2026$153.48K–
Q2 FY2025Jun 30, 2025$194.12K–
Q1 FY2025Mar 31, 2025$136.83K–

More 20/20 Biolabs figures

See a number that looks wrong?